UPDATED May 18, 2024
Companies with strong growth potential, backed by optimistic outlooks both from analysts and management.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
ESTA | US$56.57 | 1.1% | -17.6% | US$1.6b | US$63.00 | PS10x | E68.2% | n/a | ||
MYO | US$3.64 | -5.0% | 717.4% | US$104.8m | US$6.50 | PS5.4x | E64.8% | n/a | ||
NXGL | US$2.37 | 7.6% | 24.6% | US$14.7m | US$6.00 | PS3.1x | E67.5% | n/a | ||
ECOR | US$7.00 | 2.3% | 16.5% | US$42.0m | US$23.16 | PS2x | E67.0% | n/a | ||
GMED | US$64.40 | -0.5% | 14.7% | US$8.7b | US$68.75 | PE130.5x | E40.9% | n/a | ||
HIMS | US$14.57 | 18.6% | 49.1% | US$3.1b | US$16.33 | PS3.3x | E39.9% | n/a | ||
SLP | US$50.95 | 5.4% | 20.8% | US$1.0b | US$53.67 | PE96.8x | E29.5% | 0.5% | ||
ASTH | US$40.90 | 5.2% | 22.6% | US$2.0b | US$54.20 | PE32x | E18.6% | n/a | ||
AIRS | US$4.66 | -1.7% | -40.3% | US$268.3m | US$5.00 | PE171.5x | E53.8% | n/a | ||
VMD | US$7.11 | -0.5% | -32.9% | US$276.0m | US$12.75 | PE26.7x | E32.2% | n/a | ||
SRTS | US$5.93 | 12.1% | 111.8% | US$97.2m | US$9.00 | PE20.9x | E30.9% | n/a |